Asia-Pacific genetic testing market is projected to register a CAGR of 16.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Asia-Pacific Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive And Presymptomatic Testing, Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Fragile X Syndrome, Other Diseases) End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, Private Laboratories), Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific genetic testing market are:
Increase In The Adoption Of Next Generation Sequencing
Technological Advancements in Genetic Testing
Market Players:
The key market players for Asia-Pacific genetic testing market are listed below:
Thermo Fisher Scientific Inc.
Invitae Corporation
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Illumina, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Myriad Genetics, Inc.
Abbott
Eurofins Scientific
BIO-HELIX
Biocartis
Cepheid ( A subsidiary of Danaher)
PacBio
Genes2Me
Eugene Labs
Mapmygenome
MedGenome
BioReference
Natera, Inc.
Others
TABLE OF CONTENT
Segmentation
Short Description
Asia-Pacific Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive And Presymptomatic Testing, Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntingtons Disease, Fragile X Syndrome, Other Diseases) End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, Private Laboratories)
Industry Trends and Forecast to 2029.
Market Definition:
Genetic testing is a kind of medical test that identifies changes in genes, chromosomes, or proteins. The outcome of a genetic test can confirm or rule out a suspected genetic condition or aid in determining a persons chance of developing or passing on a genetic disorder. Over 77,000 genetic tests are currently in use, and others are being developed.
The increasing innovations and technologies and rising number of players in the market, and novel product launches are also propelling the growth of the Asia-Pacific genetic testing market.
Market Segmentation:
Asia-Pacific genetic testing market is categorized into four notable segments which are based on type, technology, diseases and end user. In 2022, diagnostic testing segment is expected to dominate the market due to technological advancement in the genetic testing.
On the basis of type, the Asia-Pacific genetic testing market is segmented into carrier testing, diagnostic testing, new born screening, predictive and presymptomatic testing, and other types.
On the basis of technology, the Asia-Pacific genetic testing market is segmented into DNA sequencing, polymerase chain reaction, microarrays, whole genome sequencing, fluorescence in situ hybridization (FISH), others.
On the basis of technology, the Asia-Pacific genetic testing market is segmented into DNA sequencing, polymerase chain reaction, microarrays, whole genome sequencing, fluorescence in situ hybridization (FISH), others.
On the basis of end user, the Asia-Pacific genetic testing market is segmented hospitals, clinics, diagnostic centers, private clinics, laboratory service providers, private laboratories.
Market Players
The key market players for the Asia-Pacific genetic testing market are listed below:
Thermo Fisher Scientific Inc.
Invitae Corporation
Bio-Rad Laboratories, Inc.
PerkinElmer Inc.
Illumina, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Myriad Genetics, Inc.
Abbott
Eurofins Scientific
BIO-HELIX
Biocartis
Cepheid ( A subsidiary of Danaher)
PacBio
Genes2Me
Eugene Labs
Mapmygenome
MedGenome
BioReference
Natera, Inc.
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
